Dyne Therapeutics, INC Form 4 insider transactions

Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units and pursuant to a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics' Chief Operating Officer, Susanna Gatti High, exercised stock options and sold shares to cover tax obligations and pursuant to a pre-arranged trading plan.

Chief Business Officer Jonathan McNeill sold 1,823 shares of Dyne Therapeutics stock to cover tax obligations related to vesting restricted stock units.

Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold shares of common stock on June 10 and June 11, 2024, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Catherine Stehman-Breen, a director of Dyne Therapeutics, acquired stock options for 25,133 shares on May 22, 2024.

Director Carlo Incerti acquired stock options in Dyne Therapeutics, Inc. on May 22, 2024.

Director Dirk Kersten acquired 25,133 stock options in Dyne Therapeutics on May 22, 2024, with vesting scheduled for May 22, 2025, or the date of the 2025 Annual Meeting of Stockholders.

Director Edward Hurwitz acquired stock options for 25,133 shares of Dyne Therapeutics, Inc. on May 22, 2024.

Director Jason Rhodes acquired 25,133 stock options in Dyne Therapeutics on May 22, 2024, with vesting scheduled for May 22, 2025, or the date of the 2025 Annual Meeting of Stockholders.

Director David Charles Lubner acquired stock options in Dyne Therapeutics, Inc. on May 22, 2024.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, reports the sale of common stock and exercise of stock options on May 20, 2024, according to a Form 4 filing.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Susanna Gatti High, Chief Operating Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, reports the acquisition of stock options due to an inadvertent administrative error.

Dyne Therapeutics CEO John Cox was granted stock options to purchase 679,853 shares of common stock on March 25, 2024.

Dyne Therapeutics' Chief Operating Officer, Susanna Gatti High, sold shares of common stock to cover tax withholding obligations and other transactions.

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, reports multiple transactions involving the company's stock, including sales and option exercises, executed under a pre-arranged trading plan.

Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units and under a pre-arranged 10b5-1 trading plan.

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, reported multiple transactions involving the company's common stock, including sales and option exercises, on March 8 and March 11, 2024.

CEO Joshua Brumm exercised stock options and sold shares of Dyne Therapeutics (DYN) on March 8 and March 11, 2024, according to a Form 4 filing with the SEC.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Dyne Therapeutics CEO Joshua Brumm sold 9,086 shares of common stock on March 7, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,373 shares of common stock on March 7, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Susanna Gatti High, Chief Operating Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold shares to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, sold 2,434 shares to cover tax obligations related to vesting restricted stock units.

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.